Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
3.850
+0.110 (2.94%)
At close: Oct 24, 2025, 4:00 PM EDT
3.920
+0.070 (1.82%)
After-hours: Oct 24, 2025, 7:45 PM EDT
Rocket Pharmaceuticals Stock Forecast
Stock Price Forecast
The 12 analysts that cover Rocket Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $12.88, which forecasts a 234.55% increase in the stock price over the next year. The lowest target is $2.50 and the highest is $44.
Price Target: $12.88 (+234.55%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Rocket Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 5 | 5 | 4 | 4 | 4 | 4 |
| Hold | 4 | 4 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 13 | 13 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $11 | Strong Buy | Maintains | $11 | +185.71% | Oct 14, 2025 |
| Leerink Partners | Leerink Partners | Hold Maintains $9 → $7 | Hold | Maintains | $9 → $7 | +81.82% | Oct 3, 2025 |
| B of A Securities | B of A Securities | Hold → Strong Buy Upgrades $4 → $10 | Hold → Strong Buy | Upgrades | $4 → $10 | +159.74% | Aug 20, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $11 | Strong Buy | Maintains | $11 | +185.71% | Aug 20, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +185.71% | Aug 11, 2025 |
Financial Forecast
Revenue This Year
510.00K
Revenue Next Year
18.83M
from 510.00K
Increased by 3,592.75%
EPS This Year
-2.14
from -2.73
EPS Next Year
-1.62
from -2.14
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.3M | 150.2M | |||
| Avg | 510,000 | 18.8M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 29,343.1% | |||
| Avg | - | 3,592.7% | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.90 | -1.04 | |||
| Avg | -2.14 | -1.62 | |||
| Low | -2.31 | -2.09 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.